The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Defining patient-elicited concepts unique to adolescents and young adults with cancer.
 
Viswatej Avutu
No Relationships to Disclose
 
Kathleen Lynch
No Relationships to Disclose
 
Marie Barnett
No Relationships to Disclose
 
Jacqueline Vera
No Relationships to Disclose
 
Julia Lynne Glade Bender
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; SpringWorks Therapeutics
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Deciphera; Eisai; EMD Serono; GlaxoSmithKline; Lilly; NanoCarrier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329
 
Thomas Michael Atkinson
No Relationships to Disclose